CELUW Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 geg. 2024 @ 23:00):

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases...

Stats
Šios dienos apimtis	49 216.00
Vidutinė apimtis	0.00
Rinkos kapitalizacija	67.74M
EPS	$-0.000270 ( 2023-06-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Lim Kok Thay	Buy	21 410 983	Class A Common Stock
2024-01-12	Lim Kok Thay	Buy	16 500 000	Warrants (Right to Buy)
2024-01-12	Lim Kok Thay	Buy	6 529 818	Warrants (Right to Buy)
2024-01-12	Lim Kok Thay	Buy	5 352 746	Warrants (Right to Buy)
2024-01-12	Lim Kok Thay	Sell	6 529 818	Warrants (Right to Buy)

INSIDER POWER
55.73
Last 92 transactions
Buy: 110 408 052 \| Sell: 53 673 583

Celularity Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Celularity Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$17.98M
Bruto pelnas:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2022
Pajamos:	$17.98M
Bruto pelnas:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2021
Pajamos:	$21.34M
Bruto pelnas:	$11.68M (54.76 %)
EPS:	$-0.00100

FY	2020
Pajamos:	$14.28M
Bruto pelnas:	$9.35M (65.46 %)
EPS:	$-0.0000335

Financial Reports:

No articles found.

Celularity Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company\'s lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn\'s disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.